These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 630791)

  • 1. Theophylline disposition in obesity.
    Gal P; Jusko WJ; Yurchak AM; Franklin BA
    Clin Pharmacol Ther; 1978 Apr; 23(4):438-44. PubMed ID: 630791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of obesity on apparent volume of distribution of theophylline.
    Rohrbaugh TM; Danish M; Ragni MC; Yaffe SJ
    Pediatr Pharmacol (New York); 1982; 2(1):75-83. PubMed ID: 7110759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Theophylline clearance: effect of marked obesity.
    Blouin RA; Elgert JF; Bauer LA
    Clin Pharmacol Ther; 1980 Nov; 28(5):619-23. PubMed ID: 7438680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of body fat on the volume of distribution of theophylline.
    Jewesson PJ; Ensom RJ
    Ther Drug Monit; 1985; 7(2):197-201. PubMed ID: 4024213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of body weight on the volume of distribution of theophylline.
    Rizzo A; Mirabella A; Bonanno A
    Lung; 1988; 166(5):269-76. PubMed ID: 3146673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Volume of distribution of theophylline in acute exacerbations of reversible airway disease. Effect of body weight.
    Zell M; Curtis RA; Troyer WG; Fischer JH
    Chest; 1985 Feb; 87(2):212-6. PubMed ID: 3967529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aminophylline loading in asthmatic patients: a protocol trial.
    Stine RJ; Marcus RH; Parvin CA
    Ann Emerg Med; 1989 Jun; 18(6):640-6. PubMed ID: 2658694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Digoxin disposition in obesity: clinical pharmacokinetic investigation.
    Abernethy DR; Greenblatt DJ; Smith TW
    Am Heart J; 1981 Oct; 102(4):740-4. PubMed ID: 7282520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distribution.
    Lind MJ; Margison JM; Cerny T; Thatcher N; Wilkinson PM
    Cancer Chemother Pharmacol; 1989; 25(2):139-42. PubMed ID: 2557169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Obesity, sex, and acetaminophen disposition.
    Abernethy DR; Divoll M; Greenblatt DJ; Ameer B
    Clin Pharmacol Ther; 1982 Jun; 31(6):783-90. PubMed ID: 7075126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Procainamide disposition in obesity.
    Christoff PB; Conti DR; Naylor C; Jusko WJ
    Drug Intell Clin Pharm; 1983; 17(7-8):516-22. PubMed ID: 6191939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of theophylline in hepatic disease.
    Mangione A; Imhoff TE; Lee RV; Shum LY; Jusko WJ
    Chest; 1978 May; 73(5):616-22. PubMed ID: 648214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Obesity effects on nitrazepam disposition.
    Abernethy DR; Greenblatt DJ; Locniskar A; Ochs HR; Harmatz JS; Shader RI
    Br J Clin Pharmacol; 1986 Nov; 22(5):551-7. PubMed ID: 3790401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Theophylline clearance in obese patients in relation to smoking and congestive heart failure.
    Slaughter RL; Lanc RA
    Drug Intell Clin Pharm; 1983 Apr; 17(4):274-6. PubMed ID: 6839957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carbamazepine pharmacokinetics in obese and lean subjects.
    Caraco Y; Zylber-Katz E; Berry EM; Levy M
    Ann Pharmacother; 1995 Sep; 29(9):843-7. PubMed ID: 8547729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prednisolone disposition in obese men.
    Milsap RL; Plaisance KI; Jusko WJ
    Clin Pharmacol Ther; 1984 Dec; 36(6):824-31. PubMed ID: 6499362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cimetidine disposition in obesity.
    Abernethy DR; Greenblatt DJ; Matlis R; Gugler R
    Am J Gastroenterol; 1984 Feb; 79(2):91-4. PubMed ID: 6364798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vancomycin pharmacokinetics in normal and morbidly obese subjects.
    Blouin RA; Bauer LA; Miller DD; Record KE; Griffen WO
    Antimicrob Agents Chemother; 1982 Apr; 21(4):575-80. PubMed ID: 7081978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phenytoin disposition in obesity. Determination of loading dose.
    Abernethy DR; Greenblatt DJ
    Arch Neurol; 1985 May; 42(5):468-71. PubMed ID: 3994563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Dose Adjustment Strategies for Obesity in High-dose Cyclophosphamide Among Adult Hematopoietic Cell Transplantation Recipients: Pharmacokinetic Analysis.
    Takahashi T; Jaber MM; Al-Kofahi M; Weisdorf D; Brunstein C; Bachanova V; Brundage RC; Jacobson PA; Kirstein MN
    Transplant Cell Ther; 2022 Dec; 28(12):845.e1-845.e8. PubMed ID: 36167308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.